- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03016494
Safety and Pharmacokinetics Study of Fixed Dose Combination of DWJ1386 Compared With Co-administration of DWC20155 and DWC20156 in Healthy Subjects
January 9, 2017 updated by: Daewoong Pharmaceutical Co. LTD.
A Randomized, Open-label, Oral Dose, Crossover Study to Evaluate the Pharmacokinetics and Safety of Fixed-dose Combination of DWJ1386 Compared With Co-administration of DWC20155 and DWC20156 in Healthy Subjects
The purpose of this study is to compare the safety and pharmacokinetics between co-administration and fixed dose combination of DWC20155 and DWC20156 in healthy subjects
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
56
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Daewoong Clinical
- Phone Number: 82-2-550-8106
Study Locations
-
-
Busanjin-gu
-
Busan, Busanjin-gu, Korea, Republic of, 614-735
- Recruiting
- Busan Paik Hospital
-
Contact:
- Jae-Gook Shin, Professor
- Phone Number: 82-51-890-6709
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- BMI≥18.5 and ≤27.0 kg/m2
- No clinically significant findings
- Age 19-55 years at screening
Exclusion Criteria:
- Who has allergy to investigational product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Test/Reference Drug
DWJ1386 Tab.
followed by co-administration of DWC20155 and DWC20156 Tab.
|
|
Experimental: Reference/Test Drug
co-administration of DWC20155 and DWC20156 Tab.
followed by DWJ1386 Tab.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Plasma Concentration (Cmax)
Time Frame: 0-24 hours
|
0-24 hours
|
Area under the plasma concentration versus time curve (AUC)
Time Frame: 0-24 hours
|
0-24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Anticipated)
March 1, 2017
Study Registration Dates
First Submitted
January 9, 2017
First Submitted That Met QC Criteria
January 9, 2017
First Posted (Estimate)
January 10, 2017
Study Record Updates
Last Update Posted (Estimate)
January 10, 2017
Last Update Submitted That Met QC Criteria
January 9, 2017
Last Verified
January 1, 2017
More Information
Terms related to this study
Other Study ID Numbers
- DW_DWJ1386001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Co-administration of DWC20155 and DWC20156
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthyKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.Unknown
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthyKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthyKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.TerminatedGastritisKorea, Republic of
-
Korea United Pharm. Inc.Completed
-
Korea United Pharm. Inc.Active, not recruiting
-
Meiji Seika Pharma Co., Ltd.RecruitingAcute Pyelonephritis | Complicated Intra-abdominal Infection | Complicated Urinary Tract Infection | Ventilator-associated Bacterial Pneumonia | Hospital-acquired Bacterial PneumoniaJapan
-
Assistance Publique Hopitaux De MarseilleNot yet recruiting
-
Alba Maria RoperoCenters for Disease Control and Prevention; Ministry of Public Health, ArgentinaCompletedVaccine Response ImpairedArgentina